Loading data for PRTA — first visit, this takes a few seconds.

알림

Prothena Corporation (PRTA)

NasdaqGS: PRTA · 실시간 가격 · USD

8.71

-0.17 (-1.91%)

종가 기준: Aug 18, 2026, 3:59 PM

-1.91% (1D)

매수호가	6.34
시가총액	447.15M
매출 (ttm)	54.53M
순이익 (ttm)	-43.99M
베타	-0.35
EPS (ttm)	-0.8
P/E (ttm)	n/a
선행 P/E	-5.73
P/B (ttm)	1.57
P/S (ttm)	8.20
Earnings Date	Nov 5, 2026

매도호가	11.08
거래량	232,352
평균 거래량 (20일)	552,288
시가	8.88
전일 종가	8.88
일중 범위	8.58 - 9.00
52주 범위	7.73 - 11.80
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

PRTA 소개

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Dec 18, 2012

직원 수 67

상장 거래소 NasdaqGS

티커 PRTA

웹사이트 https://www.prothena.com

전체 기업 정보

재무 실적

2025년 Prothena의 매출은 9.68M로, 전년 135.16M 대비 -92.83% 감소했습니다. 순이익은 -244.09M로, 99.57% 증가했습니다.

재무제표

어닝 서프라이즈

Prothena가 Aug 6, 2026에 분기 실적을 발표했습니다:

매출 $1.01M 예상치 하회 $0, 및 -77.15% 전년 대비 감소.

EPS -0.31 예상치 상회 0.07, 및 82.08% 전년 대비 성장.

다음 실적 발표

Prothena Corporation의 실적 발표 예정일은 Nov 5, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

4일 전 · Zacks

KMDA or PRTA: Which Is the Better Value Stock Right Now?

KMDA vs. PRTA: Which Stock Is the Better Value Option?

1주 전 · Zacks

PRTA's Q2 Loss Narrower Than Expected, Pipeline Progress in Focus

Prothena beat adjusted Q2 loss estimates, reaffirmed 2026 cash-use guidance and highlights partner pipeline progress as a key milestone decision nears.

1주 전 · Zacks

Prothena (PRTA) Reports Q2 Loss, Misses Revenue Estimates

Prothena (PRTA) delivered earnings and revenue surprises of +17.95% and -1.94%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

1주 전 · Zacks

Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates

Vanda (VNDA) delivered earnings and revenue surprises of -103.92% and -19.35%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

1개월 전 · Zacks

PRTA Stock Rises Nearly 11% in Six Months: What's Driving It?

Prothena shares climb as late-stage partnered programs advance, milestone payments strengthen finances and its neurodegenerative pipeline continues to expand.

2 페이지 중 1

Prothena Corporation (PRTA)